You need JavaScript to view this

Radiogenic Side Effects After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007

Abstract

Purpose: To evaluate side effects of hypofractionated stereotactic photon radiotherapy for patients with choroidal melanoma. Patients and Methods: Two hundred and twelve patients with choroidal melanoma unsuitable for ruthenium-106 brachytherapy or local resection were treated stereotactically at the Medical University of Vienna between 1997 and 2007 with a Linac with 6-MV photon beams in five fractions with 10, 12, or 14 Gy per fraction. Examinations for radiogenic side effects were performed at baseline and every 3 months in the first 2 years, then every 6 months until 5 years and then once a year thereafter until 10 years after radiotherapy. Adverse side effects were assessed using slit-lamp examination, funduscopy, gonioscopy, tonometry, and, if necessary, fundus photography and fluorescein angiography. Evaluations of incidence of side effects are based on an actuarial analysis. Results: One hundred and eighty-nine (89.2%) and 168 (79.2%) of the tumors were within 3 mm of the macula and the optic disc, respectively. The five most common radiotherapy side effects were retinopathy and optic neuropathy (114 cases and 107 cases, respectively), cataract development (87 cases), neovascular glaucoma (46 cases), and corneal epithelium defects (41 cases). In total, 33.6%, 38.5%, 51.2%, 75.5%, and 77.6% of the patients were free  More>>
Authors:
Dunavoelgyi, Roman; [1]  Dieckmann, Karin; [2]  Gleiss, Andreas; [3]  Sacu, Stefan; Kircher, Karl; Georgopoulos, Michael; [1]  Georg, Dietmar; [2]  Zehetmayer, Martin; [1]  Poetter, Richard [2] 
  1. Department of Ophthalmology, Medical University of Vienna, Vienna (Austria)
  2. Department of Radiology, Medical University of Vienna, Vienna (Austria)
  3. Section of Clinical Biometrics, Medical University of Vienna, Vienna (Austria)
Publication Date:
May 01, 2012
Product Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 83; Journal Issue: 1; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOMEDICAL RADIOGRAPHY; BLOOD VESSELS; BRACHYTHERAPY; CATARACTS; EPITHELIUM; FLUORESCEIN; LINEAR ACCELERATORS; MELANOMAS; PATIENTS; PHOTON BEAMS; PHOTONS; PROTON BEAMS; RUTHENIUM 106; SIDE EFFECTS
OSTI ID:
22056312
Country of Origin:
United States
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0360-3016; CODEN: IOBPD3; Other: PII: S0360-3016(11)02809-4; TRN: US12R2640016693
Availability:
Available from http://dx.doi.org/10.1016/j.ijrobp.2011.06.1957
Submitting Site:
USN
Size:
page(s) 121-128
Announcement Date:
Feb 16, 2013

Citation Formats

Dunavoelgyi, Roman, Dieckmann, Karin, Gleiss, Andreas, Sacu, Stefan, Kircher, Karl, Georgopoulos, Michael, Georg, Dietmar, Zehetmayer, Martin, and Poetter, Richard. Radiogenic Side Effects After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007. United States: N. p., 2012. Web. doi:10.1016/J.IJROBP.2011.06.1957.
Dunavoelgyi, Roman, Dieckmann, Karin, Gleiss, Andreas, Sacu, Stefan, Kircher, Karl, Georgopoulos, Michael, Georg, Dietmar, Zehetmayer, Martin, & Poetter, Richard. Radiogenic Side Effects After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007. United States. doi:10.1016/J.IJROBP.2011.06.1957.
Dunavoelgyi, Roman, Dieckmann, Karin, Gleiss, Andreas, Sacu, Stefan, Kircher, Karl, Georgopoulos, Michael, Georg, Dietmar, Zehetmayer, Martin, and Poetter, Richard. 2012. "Radiogenic Side Effects After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007." United States. doi:10.1016/J.IJROBP.2011.06.1957. https://www.osti.gov/servlets/purl/10.1016/J.IJROBP.2011.06.1957.
@misc{etde_22056312,
title = {Radiogenic Side Effects After Hypofractionated Stereotactic Photon Radiotherapy of Choroidal Melanoma in 212 Patients Treated Between 1997 and 2007}
author = {Dunavoelgyi, Roman, Dieckmann, Karin, Gleiss, Andreas, Sacu, Stefan, Kircher, Karl, Georgopoulos, Michael, Georg, Dietmar, Zehetmayer, Martin, and Poetter, Richard}
abstractNote = {Purpose: To evaluate side effects of hypofractionated stereotactic photon radiotherapy for patients with choroidal melanoma. Patients and Methods: Two hundred and twelve patients with choroidal melanoma unsuitable for ruthenium-106 brachytherapy or local resection were treated stereotactically at the Medical University of Vienna between 1997 and 2007 with a Linac with 6-MV photon beams in five fractions with 10, 12, or 14 Gy per fraction. Examinations for radiogenic side effects were performed at baseline and every 3 months in the first 2 years, then every 6 months until 5 years and then once a year thereafter until 10 years after radiotherapy. Adverse side effects were assessed using slit-lamp examination, funduscopy, gonioscopy, tonometry, and, if necessary, fundus photography and fluorescein angiography. Evaluations of incidence of side effects are based on an actuarial analysis. Results: One hundred and eighty-nine (89.2%) and 168 (79.2%) of the tumors were within 3 mm of the macula and the optic disc, respectively. The five most common radiotherapy side effects were retinopathy and optic neuropathy (114 cases and 107 cases, respectively), cataract development (87 cases), neovascular glaucoma (46 cases), and corneal epithelium defects (41 cases). In total, 33.6%, 38.5%, 51.2%, 75.5%, and 77.6% of the patients were free of any radiation retinopathy, optic neuropathy, cataract, neovascular glaucoma, or corneal epithelium defects 5 years after radiotherapy, respectively. Conclusion: In centrally located choroidal melanoma hypofractionated stereotactic photon radiotherapy shows a low to moderate rate of adverse long-term side effects comparable with those after proton beam radiotherapy. Future fractionation schemes should seek to further reduce adverse side effects rate while maintaining excellent local tumor control.}
doi = {10.1016/J.IJROBP.2011.06.1957}
journal = {International Journal of Radiation Oncology, Biology and Physics}
issue = {1}
volume = {83}
journal type = {AC}
place = {United States}
year = {2012}
month = {May}
}